VIM and neoplasm: Moreover, a high level of Vimentin was associated with poor DSS in younger patients (≤50 yrs; AHR = 2.53; 95% CI = 1.51–4.24; p<0.002, S4 Table), in patients with moderate or poor cell differentiation (AHR = 1.99; 95% CI = 1.34–2.97; p = 0.001, S4 Table), and in patients with advanced stage of disease (III-IV, AHR = 1.90; 95% CI = 1.07–3.38; p = 0.03, S4 Table) as well as in those without lymph node metastasis (N0; AHR = 1.97; 95% CI = 1.20–3.23; p = 0.008, S4 Table) but in those with smaller tumor size (T1-T2; AHR = 2.12; 95% CI = 1.34–3.37; p = 0.001, S4 Table).